Loyal, a San Francisco, CA-based clinical-stage animal health company, raised $22M in B-2 funding.
The round, in addition to its $45M Series B in 2024, was led by Valor Equity Partners and Collaborative Fund, among others. Along with his investment in Loyal, Jonathan Shulkin, Partner and Co-President at Valor Equity Partners, is joining the company’s Board of Directors.
The company, which has raised $150M in total, intends to use the funds to expand operations and its R&D efforts.
Led by Founder and CEO Celine Halioua, Loyal is an animal health company developing drugs intended to help dogs live longer, healthier lives. By targeting the underlying mechanisms of aging, it hopes to extend the lifespan of dogs and improve their quality of life as they age. It currently has three drugs in development (LOY-001, LOY-002, and LOY-003) and is making progress toward approval from the FDA’s Center for Veterinary Medicine.
LOY-002, a daily flavored tablet developed for dogs aged 10 and older weighing at least 14 pounds, aims to reduce the incidence and severity of age-associated diseases that diminish senior dogs’ quality of life, offering a practical alternative to established longevity interventions like caloric restriction. LOY-001 and LOY-003 are designed to extend the healthy lifespan of large-breed dogs.
FinSMEs
26/02/2025